IGKJ4 and hepatocellular carcinoma: At the end of the drug treatment period, both donafenib and GSK‐J4 alone were found to slightly reduce HCC growth in vivo, while combined treatment with donafenib and GSK‐J4 completely suppressed HCC growth in vivo.